First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company is starting four new pivotal trials this year.
Tecvayli and Hernexeos might get speedy approval decisions.
